From Pilots to Practice: Scaling AI Across Clinical Trials

Nik Morton, Executive Vice President, Chief Strategy and Transformation Officer, at Worldwide Clinical Trials, has successfully developed new capabilities, built high-performing teams, and driven significant operational performance and customer satisfaction improvements through infrastructure, process, and technology changes. His deep career experience includes servicing biotech and pharmaceutical customers with exceptionally broad cross-functional and multi-geographical management responsibilities. Most recently Nik served as CEO of Catalyst Clinical Research, a specialized oncology contract research organization (CRO), known for its expertise in early phase oncology trials, strong biometrics, and functional service provider (FSP) capabilities.

Prior to joining Catalyst, Nik held a series of key leadership roles at PPD across different operational and corporate functions. He led global project management, site and patient access, and biometrics functions. Nik’s data science and automation expertise aligned with these earlier roles, leading him to launch a new business unit focused on digitally enabled and decentralized clinical trial capabilities, demonstrating his innovative entrepreneurial and transformational leadership. This initiative introduced a different clinical trial paradigm service model that leveraged cutting-edge digital tools and remote technologies to enhance patient access, streamline trial execution, and open new revenue streams in a rapidly evolving landscape.

Nik earned his Master of Science in Medical Statistics from the University of Leicester and a Bachelor of Statistics from the University of Glasgow.

Tom Doyle heads product development at Medidata, a leader in clinical research technology and a life sciences arm of Dassault Systèmes. In this role, Tom leads Medidata’s work in developing industry-leading solutions for patients, sites, sponsors,and CROs, improving and accelerating the design, execution, and oversight of clinical trials – essential in bringing new and novel treatments for patients.

Tom joined Medidata in 2019, bringing 20 years of global experience in medtech and data science. Before coming to Medidata, Tom held leadership roles at Janssen and at Boehringer Ingelheim, championing technology to drive new experiences and better insights. He’s passionate about the power of innovation to transform clinical research towards better outcomes and better experiences for patients.

Tom has a BMath in computer science from the University of Waterloo in Ontario, Canada.

Nisarg Shah is a Vice President with Everest Group and manages the life sciences IT outsourcing offerings. He focuses on advisory across the life sciences value chain (drug/device discovery, clinical development, manufacturing, sales and marketing, and supply chain) and has a deep focus on advisory focused on clinical technology.

Leveraging his significant consulting and research experience, he has advised many global service providers, product vendors, and enterprises on digital transformation, product strategy, and go-to-market strategy. He also has significant experience advising clients on mergers and acquisitions, competitor assessment, and vendor assessment engagements.

He has authored industry reports on clinical development, decentralized clinical trials, and supply chain and drives thought leadership pieces across the life sciences technology space for the firm.

Prior to joining Everest Group, Nisarg worked as a technology analyst with Credit Suisse. He holds a master's in business administration from Xavier School of Management (XLRI), Jamshedpur, and a bachelor's degree in engineering from Sardar Patel Institute of Technology, Mumbai.

Kelly Hogan is a Conference Producer at Fierce Life Sciences Events, where she leads content research and conference development for healthcare and life sciences audiences. She is passionate about creating engaging industry programs that bring together thought leaders, innovators, and decision-makers to advance conversations around healthcare and life science innovation.